• Our CiPA Instruments

    Patchliner & SyncroPatch 384PE (CiPA ion channel working group); CardioExcyte 96 (CiPA myocyte working group)

  • CiPA hERG Protocol

    This protocol was used for hERG studies on the Patchliner and SyncroPatch 384PE.

  • HTS CiPA hERG Assay

    Effects of Cisapride using the CiPA hERG protocol on the SyncroPatch 384PE

  • Myocyte & Ion Channel Effects

    Arrhythmic Field potentials in iPSC-derived Cardiomyocytes (CardioExcyte 96) and hERG current inhibition (SyncroPatch 384PE)

  • Gigaseal HTS patch clamp

    CiPA-specified cardiac ion channels recorded at high throughput

  • Gigaseal HTS patch clamp

    High throughput recordings of cardiac ion channels at physiological temperature

  • CardioExcyte 96 screening tool

    CardioExcyte 96 with integrated liquid handling for cardiac safety screening

2018 - Combining electrophysiology and contractility recordings for more complete assessment of hiPSC-CMs

icon sp96   SyncroPatch 384PE,   icon pl   Patchliner and   Icon CardioExcyte 96 simpel RGB   CardioExcyte 96 poster, Europhysiology Meeting 2018  logo pdf   (1.4 MB)

Abstract:

Human induced pluripotent stem cells (hiPSCs) are becoming increasingly important for cardiac safety testing due to their recapitulation of native behaviour, relative abundance and ease-of-use. We combine automated patch clamp (APC), impedance and extracellular field potential (EFP) measurements to study hiPSC-derived cardiomyocytes (hiPSC-CMs) from different sources. In line with the comprehensive in vitro proarrhythmia assay (CiPA) initiative, cardiac ion channels expressed in heterologous expression systems have been recorded on APC devices at room temperature and at physiological temperature and the effect of different pro-arrhythmic compounds on ion channels was investigated. In addition hiPSC-CMs were used on APC platforms recording from 8 or 384 wells simultaneously. Voltage-gated Na+ (NaV), Ca2+ (CaV) and K+ (KV) currents were recorded in voltage-clamp and action potentials recorded in current clamp mode. Using the dynamic clamp technique coupled with an APC device, electrically modelled IK1 was injected into the cell under current clamp conditions and this resulted in a more hyperpolarized and stable resting membrane potential. Within the myocyte phase II study of the CiPA initiative, a device combining impedance-based contractility and extracellular field potential (EFP) recordings was used to investigate the effects of different compounds deemed low, intermediate and high risk by the FDA. Different hiPSC-CMs were used in a large cross-site evaluation and the results are summarised here.

Back to Overview

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok